Development of an interleukin-1β vaccine in patients with type 2 diabetes

Molecular Therapy

Volumn 24, Issue 5, 2016, Pages 1003-1012

  Cavelti Weder, Claudia ^a   Timper, Katharina ^a   Seelig, Eleonora ^a   Keller, Cornelia ^b   Osranek, Martin ^b   Lssing, Ute ^c   Spohn, Gunther ^c   Maurer, Patrik ^c   Müller, Philipp ^c   Jennings, Gary T ^c   Willers, Joerg ^c   Saudan, Philippe ^c   Donath, Marc Y ^a   Bachmann, Martin F ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; IMMUNOGLOBULIN G; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1BETA VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VACCINE;

ALBUMINURIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BODY MASS; CHOLELITHIASIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; CYTOKINE RESPONSE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE INDURATION; INJECTION SITE PAIN; INTERVERTEBRAL DISK HERNIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MICROALBUMINURIA; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE OBSTRUCTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VACCINATION; ADULT; AGED; ANIMAL; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RHESUS MONKEY; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-1BETA; MACACA MULATTA; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINES;

EID: 84954515005     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.227     Document Type: Article

References (23)

1. Dinarello CA, Simon A and van der Meer JW (2012). Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11: 633-652.
2. Miyamae T (2012). Cryopyrin-associated periodic syndromes: diagnosis and management. Paediatr Drugs 14: 109-117.
3. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, et al. (2007). Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517-1526.
4. van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG and Tack CJ (2011). Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 96: 2119-2126.
5. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al.; CANTOS Pilot Investigative Group. (2012). Effects of interleukin-1-inhibition with canakinumab on hemoglobin A1c, lipids C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126: 2739-2748.
6. Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, et al. (2012). Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35: 1654-1662.
7. Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A, et al. (2013). Double-blind, randomized study evaluating the glycemic and antiinflammatory effects of subcutaneous LY2189102, a neutralizing IL-1-antibody, in patients with type 2 diabetes. Diabetes Care 36: 2239-2246.
8. Donath MY (2014). Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 13: 465-476.
9. Spohn G, Keller I, Beck M, Grest P, Jennings GT and Bachmann MF (2008). Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 38: 877-887.
10. Elkordy M, Crump M, Vredenburgh JJ, Petros WP, Hussein A, Rubin P, et al. (1997). A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 19: 315-322.
11. Gershanovich ML, Filatova LV, Ketlinsky SA and Simbirtsev AS (2001). Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. II. Phase II study of the protective effect of recombinant human interleukin-1 beta on myelodepression induced by chemotherapy in cancer patients. Eur Cytokine Netw 12: 671-675.
12. Gershanovich ML, Filatova LV, Ketlinsky SA and Simbirtsev AS (2001). Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. I. Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator in cancer patients receiving combination chemotherapy. Eur Cytokine Netw 12: 664-670.
13. Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, et al. (2014). Preclinical efficacy and safety of an anti-IL-1-vaccine for the treatment of type 2 diabetes. Mol Ther Methods Clin Dev 1: 14048.
14. Rohn TA and Bachmann MF (2010). Vaccines against non-communicable diseases. Curr Opin Immunol 22: 391-396.
15. Bachmann MF and Dyer MR (2004). Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 3: 81-88.
16. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. (2008). Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371: 821-827.
17. Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, et al. (2007). A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25: 63-72.
18. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, et al. (2005). A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35: 2031-2040.
19. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. (2008). A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 3: e2547.
20. Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, et al. (2006). Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 117: 1470-1476.
21. Bendtzen K, Hansen MB, Ross C and Svenson M (1998). High-avidity autoantibodies to cytokines. Immunol Today 19: 209-211.
22. Hansen MB, Svenson M, Diamant M and Bendtzen K (1991). Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol 33: 777-781.
23. Svenson M, Poulsen LK, Fomsgaard A and Bendtzen K (1989). IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand J Immunol 29: 489-492.